Drug Control of Hypercholesteremia and Platelet Function

  • E. Tremoli
  • P. Maderna
  • S. Colli
  • R. Paoletti
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 58)


Atherosclerosis is a major disease which involves the response of different cell systems to vascular injury (1, 2). Normal endothelium possesses thromboresistant capacities, due to the synthesis of several factors, including heparin-like proteoglycans, a plasminogen activator and prostacyclin (3, 4, 5).


Placebo Cholesterol Ischemia Aspirin Prostaglandin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    R. Ross, Atherosclerosis: a problem of the biology of arterial wall cells and their interactions with blood components, Arteriosclerosis, 1:293 (1981).PubMedCrossRefGoogle Scholar
  2. 2.
    J.E. French, Atherosclerosis in relation to the structure and function of the arterial intima, with special reference to the endothelium, Int. Rev. Exp. Pathos., 5:253 (1966).Google Scholar
  3. 3.
    E.A. Jaffe, C.R. Minick, B. Adelman, C.G. Becker, and R. Nachman, Synthesis of basement membrane collagen by cultured human endothelial cells, J. Exp. Med., 144:209 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    F.B. Klynstra, E. Boelsma-van Houee,- Ind C.J.F. Boh, Acid mucopolysaccharides and atherosclerosis, Lancet, 2:1150 (1967).PubMedCrossRefGoogle Scholar
  5. 5.
    D.J. Loskutoff, and T.S. Edgington, Synthesis of a fibrinolytic activator and inhibitor by endothelial cells, Proc. Natl. Acad. Sci. USA, 74:3903 (1977).PubMedCrossRefGoogle Scholar
  6. 6.
    R. Ross, and J. Glomset, Atherosclerosis and the arterial smooth muscle cell, Science, 180:1332 (1973).PubMedCrossRefGoogle Scholar
  7. 7.
    R. Ross, and J. Glomset, The pathogenesis of atherosclerosis, N. Engl. J. Med., 295:369, 420 (1976).Google Scholar
  8. 8.
    M.B. Stemerman, and R. Ross, Experimental atherosclerosis? Fibrous plaque formation in primates, an electron microscopy study, J. Exp. Med., 136:769 (1972).PubMedCrossRefGoogle Scholar
  9. 9.
    M.A. Gimbrone, Endothélial dysfunction and the pathogenesis of atherosclerosis, in: ‘Atherosclerosis V’, A.M. Gotto, L.C. Smith, B. Allen Téds.) Proc. 5th International Symposium Atherosclerosis, New York, Springer Verlag, 415 (1980).Google Scholar
  10. 10.
    J.F. Mustard, M.A. Peckham, The role of blood and platelets in atherosclerosis and the complications of atherosclerosis, Thromb. Diath. Haemorrh., 33:444 (1975).PubMedGoogle Scholar
  11. 11.
    H. Holms &, Biochémistry-of the platelet release reaction, ‘Biochemistry and Pharmacology of platelets’, Ciba Foundation Symposium, Elsevier Norht Holland Biomedical Press, Amsterdam, 175 (1975).Google Scholar
  12. 12.
    H. Holmsen, The platelet, its membrane physiology and biochemistry, ‘Clinics in Hematology’, WB. Sanders Co. London, 2:235 (1972).Google Scholar
  13. 13.
    R. Ross, J. Glomset, B. Kariya, and L. Harker, A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro, Proc. Nati. Acad. Sci. USA, 75:4001 (1975).Google Scholar
  14. 14.
    H.N. Ântoniades, C.D. Scher, and C.D. Stiles, Purification of human platelet derived growth factor, Proc. Nati. Acad. Sci. USA, 76:1809 (1979).CrossRefGoogle Scholar
  15. 15.
    R. Ross, and A. Vogel, The platelet derived growth factor, Cell, 14:203 (1978).PubMedCrossRefGoogle Scholar
  16. 16.
    A.C.A. Carvalho, R.W. Colman, and R.S. Lees, Platelet function in hyperlipoproteinemia, N.N. Engl. J. Med., 290:434 (1974).CrossRefGoogle Scholar
  17. 17.
    A. Nordoy, and J.M. Rodset, Platelet function and platelet phospholipids in patients with hyperbetalipoproteinemia: effect of nicotinic acid and clofibrate, Circulation, 50:570 (1974).Google Scholar
  18. 18.
    R. Fabrizewski, and K. Worowski, Enhancement of platelet aggregation and adhesiveness by lipoproteins, J. Ather. Res., 8:988 (1968).CrossRefGoogle Scholar
  19. 19.
    E. Tremoli, P. Maderna, M. Sirtori, and C.R. Sirtori, Platelet aggregation and malondialdehyde formation in type Iia hypercholesterolemic patients, Haemostasis, 8:47 (1979).PubMedGoogle Scholar
  20. 20.
    E. Tremoli, G.C. Folco, E. Agradi, and C. Galli, Platelet thromboxanes and serum cholesterol, Lancet, 1:107 (1979).Google Scholar
  21. 21.
    A.C.A Carvalho, and R.S. lees, Plateletsyntravascular coagulation and fibrinolysis in hyperlipidemias: relationship to thromboembolic complications, Acta Med. Scand., suppl. 642:101 (1980).Google Scholar
  22. 22.
    M.J. Stuart, J.M. Gerrard, and J.G. White, Effect of cholesterol on production of thromboxane B2 by platelets in vitro, N. Engl. J. Med., 302:6 (1980).PubMedCrossRefGoogle Scholar
  23. 23.
    E. Tremoli, C. Ghiselli, P. Maderna, S. Colli, and C.R. Sirtori, Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits, Atherosclerosis, 41:53 (1982).PubMedCrossRefGoogle Scholar
  24. 24.
    K.M. Shastri, A.C.A. Carvalho, and R.S. Lees, Platelet function and platelet lipid composition in dyslipoproteinemias, J. Lipid Res., 21:467 (1980).PubMedGoogle Scholar
  25. 25.
    J.L. Rodriguez, G.C. Ghiselli, D. Torreggiani, and C.R. Sirtori, Very low density lipoproteins in normal and cholesterol-fed rabbits: lipid and protein composition and metabolism, Atherosclerosis, 23:73 (1976).PubMedCrossRefGoogle Scholar
  26. 26.
    J. Zahavi, J.D. Betteridge, N.A.G. Jones, D.J. Galton, and V.V. Kakkar, Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia, The Amer. J. Med., 70:59 (1981).CrossRefGoogle Scholar
  27. 27.
    C.A. Ludlam, Evidence for the platelet specificity of Betathromboglobulin and studies on its concentrations in healthy individuals, Br. J. Haematol., 41:271 (1979).PubMedCrossRefGoogle Scholar
  28. 28.
    J. Dawes, R.C. Smith, D.S. Pepper, The release distribution and clearance of human Beta-thromboglobulin and platelet factor 4, Thromb. Res., 12:851 (1978).PubMedCrossRefGoogle Scholar
  29. 29.
    V. Tamassia, G. Corvi, L.M. Fuccella, E. Moro, G. Tosolini, and E. Tremoli, Indobufen (K 3920), a new inhibitor of platelet aggregation: effect of food on bioavailability, pharmocokinetic and pharmacodynamie study during repeated oral administration to man, Europ. J. Clin. Pharmacol., 15:329 (1979).CrossRefGoogle Scholar
  30. 30.
    G.H.R. Rao, G.J. Johnson, and J.G. White, Influence of epinephrine on the aggregation response of aspirin-treated platelets, Prostaglandins and Medicine, 5:45 (1980).PubMedCrossRefGoogle Scholar
  31. 31.
    E. Tremoli, P. Maderna, S. Colli, in preparation.Google Scholar
  32. 32.
    J. Mehta, P. Mehta, and P. Couli, Platelet function studies in coronary heart disease. IX. Increased platelet prosta- glandin generation and abnormal platelet sensitivity to prostacyclin and endoperoxide analog in angina pectoris, Am. J. Cardiol., 46:943 (1980).PubMedCrossRefGoogle Scholar
  33. 33.
    H. Sinzinger, G. Schernthaner, and J. Kaliman, Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris, Prostaglandins, 22:773 (1981).PubMedCrossRefGoogle Scholar
  34. 34.
    A. Dembinska-Kiec, T. Gryglewska, A. Zmuda, and R.J. Gryglewski, The generation of prostacyclin by arteries and by coronary vascular bed is reduced in experimental atherosclerosis in rabbits, Prostaglandins, 14:1025 (1977).PubMedCrossRefGoogle Scholar
  35. 35.
    V. D’Angelo, S. Villa, M. Myslìwiec, I.B. Donati, and G. de Gaetano, Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques, Thromb. Haemost., 38:535 (1978). -Google Scholar
  36. 36.
    R.J. Gryglewski, Prostaglandins, Platelets and Atherosclerosis, CRC Reviews, 290 (1980).Google Scholar
  37. 37.
    K. Fukuzumi, Lipids in atherosclerotic artery. The cause of atherosclerosis from the vieuw point of fat chemistry, Fette, Seifen, Anstrichm. 11:953 (1969).CrossRefGoogle Scholar
  38. 38.
    J. Lilipovic, and M. Rutemoller, Comparative studies on fatty acid synthesis in atherosclerotic and hypoxic human aorta, Atherosclerosis, 24:457 (1976).CrossRefGoogle Scholar
  39. 39.
    M. Steiner, Ind J. Anastasi, Vitamin E, an inhibitor of the platelet release reaction, J. Clin. Invest., 57:732 (1976).PubMedCrossRefGoogle Scholar
  40. 40.
    A. Szczeklik, R.J. Gryglewski, B. Domagala, A. Zmuda, J. Hartwich, E. Wozny, M. Grzywacz, J. Madej, and T. Gryglewska, Serum lipoproteins, lipid peroxides and prostacyclin biosynthesis in patients with coronary heart disease, Prostaglandins, 22:795 (1981).PubMedCrossRefGoogle Scholar
  41. 41.
    A. Nordoy, B. Svensson, D. Wiebe, and J.C. Hoak, Lipoproteins and the inhibitory effect of human endothelial cells on platelet function, Circulation Res., 43:527 (1978).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1983

Authors and Affiliations

  • E. Tremoli
    • 1
  • P. Maderna
    • 1
  • S. Colli
    • 1
  • R. Paoletti
    • 1
  1. 1.Institute of Pharmacology and PharmacognosyUniversity of MilanMilanItaly

Personalised recommendations